Medical Xpress August 2, 2024
A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.
Prescription fills for the drug best known as Ozempic or Wegovy—semaglutide—increased by more than 400% between January 2021 and December 2023, according to research appearing in JAMA Health Forum.
Approved first for type 2 diabetes, then for weight loss, studies show that semaglutide also improves blood pressure and reduces cardiovascular disease—problems that plague millions of Americans. Yet the lion’s share of prescriptions went to people with private insurance.
“Given the proven cardiovascular benefits of Ozempic and Wegovy when used for diabetes or obesity, and the disproportionate burden of...
Today's Sponsors
Today's Sponsor